Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
'We appreciate the continued support of our limited partners, many of whom have been with us since the launch of our first dedicated venture fund in 2016,' said Patrick Heron, Managing Partner at Frazier Life Sciences. 'With FLS XII, we look forward to continuing to work with exceptional entrepreneurs to advance therapeutic programs with the potential to address significant medical needs.'
Frazier Life Sciences has raised over $3.6 billion across five dedicated venture funds since 2016, alongside more than $1.7 billion raised in long-only public funds since 2021.
The FLS team includes seven investment partners and a growing group of over 35 investment professionals, operating professionals, and senior advisors with broad biopharmaceutical experience across therapeutic areas and company stages. The firm takes a hands-on, collaborative approach to company building, leading to 25 new companies launched since 2020. Noteworthy investments include Alpine Immune Sciences (acquired by Vertex), Arcutis Biotherapeutics (NASDAQ: ARQT), Mirum Pharmaceuticals (NASDAQ: MIRM), NewAmsterdam Pharma (NASDAQ: NAMS), Tarsus Pharmaceuticals (NASDAQ: TARS), and Amunix Pharmaceuticals (acquired by Sanofi), among others.
About Frazier Life Sciences
Frazier Life Sciences (FLS) invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Since 2016, the firm has raised over $5.3 billion including venture funds focusing on company creation and private companies and long-only public funds focused on small and mid-cap public companies. Since 2010, FLS portfolio companies have achieved over 65 FDA-approved therapeutics and completed more than 60 IPOs or strategic acquisitions.
FLS is headquartered in Palo Alto, CA, with offices in San Diego, Seattle, and Boston.
For more information, please visit frazierls.com and follow us on LinkedIn.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Alivus Life Sciences Ltd (BOM:543322) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst ...
Release Date: August 02, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Alivus Life Sciences Ltd (BOM:543322) reported a year-on-year revenue growth of 2.2%, driven by a 14.5% increase in the non-GPL business. The company's gross margin improved by 400 basis points to 55.1%, attributed to rationalized input costs and operational efficiency. The EBITDA margin increased by 210 basis points to 30.1%, reflecting better gross margins. Alivus Life Sciences Ltd (BOM:543322) remains debt-free and generated strong cash flow from operations, with cash and cash equivalents of INR 660 crore. The company received successful outcomes from US FDA inspections for its facilities, enhancing its compliance and operational credibility. Negative Points The GPL business experienced a significant year-on-year decline of 22%, impacting overall revenue growth. The CDMO business remained subdued during the quarter, with commercialization expected only in the second half of the year. Pricing pressures are anticipated to keep revenue growth in the high single digits, despite mid-teens volume growth guidance. The company's R&D expenditure increased, which may impact short-term profitability. There is uncertainty regarding the timeline for product commercialization from the Solapur facility, which could delay revenue contributions. Q & A Highlights Warning! GuruFocus has detected 3 Warning Signs with BOM:543322. Q: Can you provide an update on the Solapur facility and its expected contribution to the top line? A: Dr. Yasir Raji, MD and CEO: The Solapur facility is expected to come online in 2024. We plan to file products in the first half of next year to trigger inspections. Initially, we will focus on ROW (Rest of World) business, which will start contributing to the top line in the first half of next year. Q: How do you see the business mix between Glenmark and non-Glenmark evolving, and what are your growth expectations? A: Dr. Yasir Raji, MD and CEO: We expect the GPL business to grow, and we are confident in achieving high single-digit growth overall. The business is not quarter-on-quarter, and demand patterns can vary. We anticipate growth in both GPL and non-GPL segments. Q: Can you elaborate on the progress and commercialization timeline for your high-potent API pipeline? A: Dr. Yasir Raji, MD and CEO: Of the 26 high-potent products, 12 have firm customer interest and are being validated. Commercial activity is expected to start from late FY27 as patents in some early markets begin to expire. Q: What is the outlook for your CDMO business, and do you expect any new projects to commercialize this year? A: Dr. Yasir Raji, MD and CEO: We have five projects, with two more in the pipeline. All five projects should be commercial by H2. There is a strong possibility of achieving 50 crore per quarter in revenue from these projects. Q: How are you planning to manage CapEx, and what is the expected expenditure for FY26? A: Dr. Yasir Raji, MD and CEO: We have an overflow from last year of 190 crore and plan to start our R&D project this year. With the completion of the Solapur facility and two brownfield projects, we expect to spend about 600 crore, including the overflow. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 hours ago
- Yahoo
Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). This open-label, multi-center international study plans to enroll 66 patients with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC to evaluate the safety and preliminary efficacy of the triplet therapy. Enrollment is planned in Taiwan and Australia. Tislelizumab, a PD-1 monoclonal antibody, used in this trial is provided by BeOne Medicines (formerly known as BeiGene). Further details on this collaboration were disclosed by Anbogen in a press release dated September 27, 2024. ABT-301 is an oral HDAC1/2/3 inhibitor. Preclinical studies have shown that it promotes CD8+ cytotoxic T cell infiltration and activity, enhances antigen presentation, and inhibits M-MDSCs cells, effectively modulating the tumor microenvironment and converting "cold tumors" into "hot tumors" to improve the efficacy of immune checkpoint inhibitors. ABT-301 also exhibits pro-apoptotic, anti-angiogenic, and tumor metabolic regulation effects. As a single-molecule, multi-modality anti-cancer agent, ABT-301 aims to enhance tumor treatment when combined with the two antibody drugs. Notably, in a previous Phase 1 monotherapy clinical trial involving 23 participants, ABT-301 did not exhibit neutropenia or cardiac toxicity, which are commonly observed in other HDAC inhibitors—further supporting its suitability for use in combination immunotherapy. Approximately 95% of mCRC patients are pMMR or non-MSI-H types—commonly referred to as "cold tumors"—which respond poorly to current immunotherapies. Only around 5% of patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) "hot tumors" typically benefit from immune checkpoint inhibitors. According to GlobalData, an estimated 370,000 new pMMR/non-MSI-H patients in second-line or later settings are diagnosed annually across the U.S., China, Japan, and the top five European markets (UK, France, Germany, Spain, and Italy), representing a potential market size of USD $9 billion. Anbogen stated that the FDA's IND approval marks a key milestone in the development of ABT-301, demonstrating the safety profile of the triplet therapy and advancing it into clinical stages. The company emphasized that the study targets the majority of patients (over 90%) with poor responses to immunotherapy, aiming to provide a novel treatment option and address this unmet clinical need. Looking ahead, Anbogen will continue to advance the clinical development of ABT-301 while pursuing global licensing and strategic partnerships to accelerate commercialization and market entry. The company is also launching its Series B fundraising to attract strategic partners committed to advancing innovative cancer therapies and global expansion. About Anbogen Therapeutics Anbogen Therapeutics is a clinical-stage biotechnology company committed to developing precision oncology therapies that improve the lives of cancer patients worldwide. The company currently has two core assets: ABT-301, a HDAC1/2/3 inhibitor with immune-modulating capabilities, enhances the tumor microenvironment and boosts immune responses. It significantly improves the efficacy of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC), offering a new treatment pathway for the majority of patients who do not benefit from ICIs. ABT-501 is a novel Peptide Drug Conjugate (PDC) that targets LHRH-receptor tumors using a proprietary delivery system. It has shown strong efficacy and safety in triple-negative breast cancer models, with potential for broader cancer applications. For more information, please visit Anbogen's official website at View original content: SOURCE Anbogen Therapeutics
Business Upturn
4 hours ago
- Business Upturn
SCDL's 25-Year Journey – Silver Jubilee Celebrations Across India
Symbiosis Centre for Distance Learning (SCDL) is proudly celebrating its 25th anniversary. This celebration marks an important milestone in the institute's journey of delivering quality education to every corner of the country. Business Wire India Symbiosis Centre for Distance Learning (SCDL) is proudly celebrating its 25th anniversary. This celebration marks an important milestone in the institute's journey of delivering quality education to every corner of the country. Over the past two decades and more, SCDL has shaped the careers of lakhs of students, promoted lifelong learning, and opened pathways to a brighter future. As one of India's leading autonomous distance learning institutions, SCDL has educated more than 1 million learners to date and currently engages with a vibrant community of 80,000+ active students. To honor this remarkable legacy, SCDL hosted a series of Silver Jubilee events across major Indian cities. Celebrations were organized in Dubai (May 2), Bengaluru (28 June 2025), Hyderabad (5 July), New Delhi (12 July), and Mumbai (26 July). The central message of the jubilee perfectly aligned with SCDL's mission – 'To make quality education accessible to all, irrespective of geography or background.' A Legacy of Learning and Transformation For 25 years, SCDL has led the way in India's distance education sector. By emphasizing innovation, flexibility, and career-oriented learning , the institute has continuously adapted to meet the changing needs of both fresh graduates and working professionals. Through its wide range of AICTE-approved Post Graduate Diploma and Certificate programs, SCDL has enabled learners to upskill, reskill, and stay relevant in today's competitive job market. The Silver Jubilee celebration was both a tribute to this enduring legacy and a platform to look toward the future of learning . Highlights from the Celebrations 1) Career Growth Seminars The core attraction of the events was the Career Growth Seminars , where renowned speakers shared insights: Ankur Warikoo – Entrepreneur, Author, and Content Creator, offered practical guidance on building a meaningful career in an AI-first world. Dr. Arjun Vaidya – D2C Entrepreneur and Investor, spoke on reinventing oneself in the evolving job market and fostering an entrepreneurial mindset even in traditional roles. Dale Carnegie-certified trainers – conducted impactful sessions on leadership, emotional intelligence, and thriving in high-pressure corporate environments. These seminars emphasized career acceleration, future readiness, and navigating the digital era . 2) HR Roundtable In collaboration with HR Shapers, SCDL organized a Leadership Roundtable on the theme 'Leadership Development and Capability Building – Reskills, Upskills, and Cross Skills.' The session saw participation from senior HR leaders and decision-makers representing EsselWorld, Larsen & Toubro (L&T India), Adani Group, Wadhwa Group, Dentsu Group, Kalpataru Projects International Ltd, Tech Mahindra, Khosla Profiles Pvt. Ltd, Value First Investments, ISS Facility Services India Pvt. Ltd, Orion Technologies, Kotak Mahindra Bank, Spark Capital, Persistent Systems , and many others. The discussions revolved around future-ready leadership, talent development, and strategies for navigating the evolving skill era . 3) Silver Jubilee & Alumni Awards Ceremony The celebration featured a heartfelt short film showcasing SCDL's 25-year journey , highlighting key milestones, technological progress, and inspirational alumni stories. The evening concluded with the SCDL Alumni Awards , where exemplary alumni were honored with a trophy and a silver coin for their leadership and innovation in various fields. Click here to watch a glimpse of SCDL silver jubilee events. Speaking on the occasion, Dr. Swati Mujumdar, Principal Director, S CDL , said, 'It is heart-warming to see so many alumni and corporate professionals together. SCDL's journey—from starting with the Armed Forces to now reaching over 1 million learners across 36 countries—has been truly inspiring. SCDL originated in 1995 from Symbiosis Institute of Management Studies. General Allu Walia suggested to our Founder and Chancellor, Dr. S. B. Mujumdar, that some courses should be launched for defense personnel who could not come to Pune to study. This vision led to SCDL's inception. By 2001, civilians and their children began enrolling. After I returned from the USA in 2003, I took charge of SCDL, when the institute had very few students and minimal technology use. Between 2003–04, we introduced e-learning, computerized programs, online and on-demand exams, which enabled us to reach learners across India.' She added, 'Symbiosis was started by a teacher. When an educational institute is founded by a businessman versus a teacher, there is a huge difference. Today, Symbiosis alumni are present not just across India, but globally.' The Silver Jubilee Spirit The celebration embodied SCDL's philosophy of 'Education for All' . Whether it was a young professional exploring AI, a homemaker upskilling for remote work, or a retired soldier re-entering civilian life—each story reflected SCDL's inclusive vision . Join the Silver Jubilee Batch SCDL invites new learners to be part of its Silver Jubilee batch , continuing its legacy of academic excellence. Special Benefits Join our flagship program and get below benefits: Free Premium Single Course worth INR 10,000 Free Micro Course from Symbiosis Digital Varsity Scholarships available – for EBC (Economically Backward Class) students and Armed Forces personnel Explore Our Courses Contact us for more details – 8792740467 / [email protected] Looking Ahead SCDL is set to redefine learning through tech-enabled platforms, AI-based learning experiences, and industry-integrated programs . The next 25 years promise more innovation, deeper impact, and a stronger commitment to building a skilled India . Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
